Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

FLASH-radiation therapy: hype or game changer?

BGICC 2023

19 - 20 Jan 2023

Published: 2 Feb 2023

Views: 16

Rating:

Save

Prof Philip Poortmans - University of Antwerp, Antwerp, Belgium

Prof Philip Poortmans speaks to ecancer about his talk on 'FLASH-radiation therapy: hype or game changer?' at the BGICC 2023.

FLASH radiation treatment delivers therapeutic doses of radiation in a fraction of a second. Prof Poortmans explores the effect this treatment has on tumours and the effects on normal tissue.

Related Videos

War in Ukraine: The logistical challenges of transferring medical materials

Dr Horia Vulpe , Dr Ruslan Baltaga

War in Ukraine: The logistical challenges of transferring medical materials ( Dr Horia Vulpe , Dr Ruslan Baltaga )

Global adoption of single-shot targeted IORT for breast cancer

Dr Jayant Vaidya - University College London, London, UK

Global adoption of single-shot targeted IORT for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )

Gaps in the workforce delivering cancer care

Dr Nazik Hammad - Cancer Centre of Southeastern Ontario, Kingston, Canada

Gaps in the workforce delivering cancer care ( Dr Nazik Hammad - Cancer Centre of Southeastern Ontario, Kingston, Canada )

Lymph node irradiation therapy for BC in the 21st Century

Prof Philip Poortmans - University of Antwerp, Antwerp, Belgium

Lymph node irradiation therapy for BC in the 21st Century ( Prof Philip Poortmans - University of Antwerp, Antwerp, Belgium )

Novel antibody-drug conjugates (ADCs) technologies for management of mBC

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Novel antibody-drug conjugates (ADCs) technologies for management of mBC ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...

Dr Ian Krop - Yale Cancer Center, Connecticut, USA

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk...

Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML ( Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA )

Comment: POLAR gene profile can identify which patients can safely avoid...

Prof Christos Markopoulos- National and Kapodistrian University of Athens...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer